Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2016 (2016), Article ID 7951365, 6 pages
http://dx.doi.org/10.1155/2016/7951365
Research Article

Evaluation of the Expression of the Human Epithelial Receptor 2 (HER2) in Gastric Carcinoma

Gastric and Obesity Surgery Division, Surgery Department, Santa Casa of São Paulo Medical School, São Paulo, SP, Brazil

Received 3 May 2016; Accepted 6 December 2016

Academic Editor: ChangHui Shen

Copyright © 2016 Roberto de Moraes Cordts Filho et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Estimativa 2016, Incidência de Câncer no Brasil/Instituto Nacional de Câncer José Alencar Gomes da Silva, INCA, Rio de Janeiro, Brazil, 2015.
  2. J. Ferlay, I. Soerjomataram, M. Ervik et al., GLOBOCAN 2012 v1.0, Cancer and Mortality Worldwide: IARC CancerBase No. 11, International Agency for Research on Cancer, Lyon, France, 2013, http://globocan.iarc.fr.
  3. A. L. Schechter, D. F. Stern, L. Vaidyanathan et al., “The neu oncogene: an erb-B-related gene encoding a 185,000-M(r) tumour antigen,” Nature, vol. 312, no. 5994, pp. 513–516, 1984. View at Publisher · View at Google Scholar · View at Scopus
  4. H.-S. Cho, K. Mason, K. X. Ramyar et al., “Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab,” Nature, vol. 421, no. 6924, pp. 756–760, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. X. X. He, L. Ding, Y. Lin, M. Shu, J. M. Wen, and L. Xue, “Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival,” Journal of Clinical Pathology, vol. 68, no. 5, pp. 374–380, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Yan, M. Schwaederle, D. Arguello, S. Z. Millis, Z. Gatalica, and R. Kurzrock, “HER2 expression status in diverse cancers: review of results from 37,992 patients,” Cancer and Metastasis Reviews, vol. 34, no. 1, pp. 157–164, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. Y. Kurokawa, N. Matsuura, Y. Kimura et al., “Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer,” Gastric Cancer, vol. 18, no. 4, pp. 691–697, 2015. View at Publisher · View at Google Scholar · View at Scopus
  8. H. S. Song, Y. R. Do, I. H. Kim, S. S. Sohn, and K. Y. Kwon, “Prognostic significance of immunohistochemical expression of EGFR and c-erbB-2 oncoprotein in curatively resected gastric cancer,” Cancer Research and Treatment, vol. 36, no. 4, pp. 240–245, 2004. View at Publisher · View at Google Scholar
  9. A. F. C. Okines and D. Cunningham, “Trastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer,” Therapeutic Advances in Gastroenterology, vol. 5, no. 5, pp. 301–318, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Terashima, K. Kitada, A. Ochiai et al., “Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer,” Clinical Cancer Research, vol. 18, no. 21, pp. 5992–6000, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Gu, L. Zheng, Y. Wang, M. Zhu, Q. Wang, and X. Li, “Prognostic significance of HER2 expression based on trastuzumab for gastric cancer (ToGA) criteria in gastric cancer: an updated meta-analysis,” Tumor Biology, vol. 35, no. 6, pp. 5315–5321, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. Y.-J. Bang, E. Van Cutsem, A. Feyereislova et al., “Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial,” The Lancet, vol. 376, no. 9742, pp. 687–697, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Okines, D. Cunningham, and I. Chau, “Targeting the human EGFR family in esophagogastric cancer,” Nature Reviews Clinical Oncology, vol. 8, no. 8, pp. 492–503, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. E. C. Smyth and D. Cunningham, “Targeted therapy for gastric cancer,” Current Treatment Options in Oncology, vol. 13, no. 3, pp. 377–389, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Iqbal, B. Goldman, C. M. Fenoglio-Preiser et al., “Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer,” Annals of Oncology, vol. 22, no. 12, Article ID mdr021, pp. 2610–2615, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. J. R. Hecht, Y. J. Bang, S. Qin et al., “Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): the TRIO-013/LOGiC Trial,” Journal of Clinical Oncology, vol. 31, supplement 1, abstract LBA4001, 2013. View at Google Scholar
  17. T. Satoh, R.-H. Xu, H. C. Chung et al., “Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN—a randomized, phase III study,” Journal of Clinical Oncology, vol. 32, no. 19, pp. 2039–2049, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Hofmann, O. Stoss, D. Shi et al., “Assessment of a HER2 scoring system for gastric cancer: results from a validation study,” Histopathology, vol. 52, no. 7, pp. 797–805, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Sano and Y. Kodera, “Japanese classification of gastric carcinoma: 3rd English edition,” Gastric Cancer, vol. 14, no. 2, pp. 101–112, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. T. Akiyama, C. Sudo, H. Ogawara, K. Toyoshima, and T. Yamamoto, “The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity,” Science, vol. 232, no. 4758, pp. 1644–1646, 1986. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. K. Wang, C. F. Gao, T. Yun et al., “Assessment of ERBB2 and EGFR gene amplification and protein expression in gastric carcinoma by immunohistochemistry and fluorescence in situ hybridization,” Molecular Cytogenetics, vol. 4, no. 1, article no. 14, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. E. Van Cutsem, Y.-J. Bang, F. Feng-yi et al., “HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer,” Gastric Cancer, vol. 18, no. 3, pp. 476–484, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Otsu, E. Oki, A. Ikawa-Yoshida et al., “Correlation of HER2 expression with clinicopathological characteristics and prognosis in resectable gastric cancer,” Anticancer Research, vol. 35, no. 4, pp. 2441–2446, 2015. View at Google Scholar · View at Scopus
  24. T. Saito, H. Nakanishi, Y. Mochizuki et al., “Preferential HER2 expression in liver metastases and EGFR expression in peritoneal metastases in patients with advanced gastric cancer,” Gastric Cancer, vol. 18, no. 4, pp. 711–719, 2015. View at Publisher · View at Google Scholar · View at Scopus
  25. V. Nagaraja and G. D. Eslick, “HER2 expression in gastric and oesophageal cancer: a meta-analytic review,” Journal of Gastrointestinal Oncology, vol. 6, no. 2, pp. 143–154, 2015. View at Google Scholar
  26. M. D. Begnami, E. Fukuda, J. H. T. G. Fregnani et al., “Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome,” Journal of Clinical Oncology, vol. 29, no. 22, pp. 3030–3036, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. A. A. A. Jácome, D. R. Wohnrath, C. Scapulatempo Neto et al., “Prognostic value of epidermal growth factor receptors in gastric cancer: a survival analysis by Weibull model incorporating long-term survivors,” Gastric Cancer, vol. 17, no. 1, pp. 76–86, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. E. A. M. Damasceno, F. P. Carneiro, A. V. de Magalhães et al., “IMP3 expression in gastric cancer: association with clinicopathological features and HER2 status,” Journal of Cancer Research and Clinical Oncology, vol. 140, no. 12, pp. 2163–2168, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. E. H. Jin, D. H. Lee, S.-A. Jung et al., “Clinicopathologic factors and molecular markers related to lymph node metastasis in early gastric cancer,” World Journal of Gastroenterology, vol. 21, no. 2, pp. 563–570, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. T. Matsumoto, M. Sasako, J. Mizusawa et al., “HER2 expression in locally advanced gastric cancer with extensive lymph node (bulky N2 or paraaortic) metastasis (JCOG1005-A trial),” Gastric Cancer, vol. 18, no. 3, pp. 467–475, 2015. View at Publisher · View at Google Scholar · View at Scopus